14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ADMA vs ELVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, ADMA Biologics, Inc. (ADMA) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADMA carries a Unified Composite Score of 23.7/100 (STRONG SELL) at $13.70 (15.7x Forward P/E, 44.9% operating margin), whereas ELVN carries 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ELVN currently prints a higher short-term Unified Composite Score (36.2/100 SELL vs. ADMA 23.7/100 STRONG SELL), ADMA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (44.9% vs. 0.0% operating margin) and revenue trajectory (+5.1% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although ADMA compares more favorably head-to-head, both ADMA (23.7/100 STRONG SELL) and ELVN (36.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADMA vs ELVN. Trailing 12-month operating profitability (ADMA 44.9% vs ELVN 0.0%) and valuation multiples (ADMA 15.7x vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ADMA vs ELVN Key Questions & Quantitative Answers
As of Nov 16, 2026, ADMA Biologics, Inc. (ADMA) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADMA carries a Unified Composite Score of 23.7/100 (STRONG SELL) at $13.70 (15.7x Forward P/E, 44.9% operating margin), whereas ELVN carries 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ELVN currently prints a higher short-term Unified Composite Score (36.2/100 SELL vs. ADMA 23.7/100 STRONG SELL), ADMA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (44.9% vs. 0.0% operating margin) and revenue trajectory (+5.1% vs. +0.0% YoY). Defensive Composite Rating Caution: Although ADMA compares more favorably head-to-head, both ADMA (23.7/100 STRONG SELL) and ELVN (36.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
ADMA leads the Growth & Scale pillar: ADMA posts +5.1% YoY revenue growth and +46.7% YoY earnings growth on $519M TTM revenue (68.5% gross margin, 44.9% operating margin), compared with ELVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADMA generates $519M in USD-normalized revenue versus N/A for ELVN. In operating R&D and SG&A reinvestment, ADMA deploys 23.6% of Rev ($123M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELVN.
ADMA screens cheaper on headline valuation multiples. ADMA trades at 15.7x Forward P/E, 17.2x Trailing P/E, N/M PEG, and 5.8x EV/Revenue (25.5% FCF margin), whereas ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADMA (41.9% ROE) versus ELVN (-16.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ADMA carries 45.1% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (-0.42β · 99% Vol realized risk). By comparison, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.